Evidence map›Paper›PMID 40989551›Full record

ArticleNanoscale advances2025

Impact of oil phase composition on the efficacy of nanoemulsions for verteporfin-mediated photodynamic therapy in ovarian cancer.

Laura Fuentes Varela, María Emilia Vasquez, Carmen Abuín Redondo, Andrea Estrella Arias-Diaz, Miguel Abal, Clotilde Costa, Roberto Piñeiro, Irene Villa, Ekaterina A Kukushkina, Lucia Lama and 3 more

Abstract read
In one paragraph

Article in Nanoscale advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Laura Fuentes VarelaTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0009-0002-6083-6590
María Emilia VasquezTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.
Carmen Abuín RedondoTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0002-6902-4161
Andrea Estrella Arias-DiazTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0009-0007-1156-9242
Miguel AbalTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0003-3533-7781
Clotilde CostaTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0001-7327-2259
Roberto PiñeiroTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0001-9479-139X
Irene VillaDepartment of Materials Science, University of Milano-Bicocca 20125 Milano Italy.ORCID https://orcid.org/0000-0002-6150-7847
Ekaterina A KukushkinaDepartment of Materials Science, University of Milano-Bicocca 20125 Milano Italy.
Lucia LamaUniversidade de Coruña (UDC) A Coruña Spain.
Antía CabezasUniversidade de Santiago de Compostela (USC) Santiago de Compostela Spain.
Rafael López LópezTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0003-1315-655X
Ana B Dávila-IbánezTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS) Santiago de Compostela Spain ana.belen.davila.ibanez@sergas.es.ORCID https://orcid.org/0000-0002-9906-5458

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicine has emerged as a powerful strategy to enhance both therapeutic efficacy and diagnostic precision in oncology. Among the various nanoscale platforms, nanoemulsions have shown promising potential as drug delivery systems, particularly in photodynamic therapy. However, the design of effective nanoemulsions requires careful consideration of multiple formulation parameters, especially the choice of the oil core, which remains insufficiently explored. In this study, we developed and compared two nanoemulsions differing only in their oil phase, oleic acid or miglyol, both loaded with the photosensitizer verteporfin, a clinically approved photosensitizer. We systematically evaluated their physicochemical characteristics, loading capacity, encapsulation efficiency, storage stability, and therapeutic efficacy in an ovarian cancer cell line. Our results demonstrate that the oil phase significantly influences nanoemulsion performance. Verteporfin-loaded miglyol-based nanoemulsions exhibited higher drug loading capacity, improved colloidal stability, and greater photodynamic cytotoxicity compared to the oleic acid-based counterpart. These findings underscore the critical role of formulation components in determining the functionality of nanocarriers and highlight the importance of rational nanoemulsion design to maximize therapeutic outcomes in photodynamic therapy and broader nanomedicine applications.

Identifiers

PMID40989551
PMCPMC12452016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.